ea0043oc32 | Meta-Analysis of Phase 2/3 Studies | WCTD2016
Pham Thuy
, Singh Mukunda
, Dao Marvin
, Herrera Griselda
, Asuncion Katherine
Background: Oral semaglutide GLP1 receptor agonist is coformulated for better absorption compared to prior injectable semaglutide. Phase 2 open label, dose escalation randomized clinical trials of semaglutide and liraglutide investigating the dose-response relationship between the two. DPP-4 inhibitor produces a smaller glycemic reduction and minimal weight reduction through effect of endogenous GLP-1 receptor activity, while GLP-1RAs yield greater efficacy related to the phar...